|        |
|--------|
|        |
|   |
|   |

|   |
|---|
|   |  |  |
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |   |

|   |
|---|
|   |  |  |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |   |

|                                          |
|------------------------------------------|
|                                          |  |  |
| Delaware                                 |   | 59-2758596 |
| (State or other jurisdiction of          |   | (I.R.S. Employer |
| incorporation or organization)           |   | Identification No.) |
|                                     |   |   |
| 354 Eisenhower Parkway                   |   |   |
| Livingston, New Jersey                   |   | 07039 |
| (Address of principal executive offices) |   | (Zip Code) |

|                           |
|---------------------------|
|                           |  |  |
| Large accelerated filer o |   | Accelerated filer x |
| Non-accelerated filer o   | (Do not check if a smaller reporting company) | Smaller reporting company o |

----

|                                |
|--------------------------------|
|                                |  |  |  |
|                           |   |   | Page |
| Part I - Financial Information |   |   |
| Item 1.                        | Financial Statements |   | 3 |
|                           | Condensed Consolidated Balance Sheets |   | 4 |
|                           | Condensed Consolidated Statements of Operations |   | 5 |
|                           | Condensed Consolidated Statements of Comprehensive Loss |   | 6 |
|                           | Condensed Consolidated Statements of Cash Flows |   | 7 |
|                           | Notes to Condensed Consolidated Financial Statements |   | 9 |
| Item 2.                        | Management’s Discussion and Analysis of Financial Condition and Results of Operations |   | 17 |
| Item 3.                        | Quantitative and Qualitative Disclosures About Market Risk |   | 23 |
| Item 4.                        | Controls and Procedures |   | 23 |
|                           |   |   |   |
| Part II - Other Information    |   |   |
| Item 1.                        | Legal Proceedings |   | 24 |
| Item 1A.                       | Risk Factors |   | 24 |
| Item 2.                        | Unregistered Sales of Equity Securities and Use of Proceeds |   | 24 |
| Item 3.                        | Defaults upon Senior Securities |   | 24 |
| Item 4.                        | (Removed and Reserved) |   | 24 |
| Item 5.                        | Other Information |   | 24 |
| Item 6.                        | Exhibits |   | 25 |
|                           |   |   |   |
| SIGNATURES                     |   | 26 |

----

----

|                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                   |  |  |  |  |  |  |  |
|                                                                                                                                                                                                              | March 31, 2011 |   | December 31, 2010 |
|                                                                                                                                                                                                              | (Unaudited) |   |   |
| ASSETS                                                                                                                                                                                                            |   |   |   |   |   |
| Current Assets:                                                                                                                                                                                                   |   |   |   |   |   |
| Cash and cash equivalents of which $15,254,034 in 2011 and $8,245,818 in 2010 is interest bearing                                                                                                                 | $ | 20,060,211 |   |   | $ | 21,630,979 |   |
| Accounts receivable, net of allowances for doubtful accounts of $100,000 in 2011 and 2010 (including amounts from related parties: 2011 - $555,441; 2010 - $0)                                                    | 3,016,942 |   |   | 4,141,026 |   |
| Inventories                                                                                                                                                                                                       | 2,903,388 |   |   | 2,586,207 |   |
| Prepaid expenses and other current assets                                                                                                                                                                         | 900,316 |   |   | 497,947 |   |
| Total current assets                                                                                                                                                                                              | 26,880,857 |   |   | 28,856,159 |   |
| Property and equipment, net                                                                                                                                                                                       | 473,305 |   |   | 518,542 |   |
| Other assets                                                                                                                                                                                                      | 464,321 |   |   | 484,141 |   |
| TOTAL ASSETS                                                                                                                                                                                                      | $ | 27,818,483 |   |   | $ | 29,858,842 |   |
|                                                                                                                                                                                                              |   |   |   |
| LIABILITIES AND SHAREHOLDERS' DEFICIENCY                                                                                                                                                                          |   |   |   |   |   |
| Current Liabilities:                                                                                                                                                                                              |   |   |   |   |   |
| Accounts payable                                                                                                                                                                                                  | $ | 2,829,127 |   |   | $ | 5,393,966 |   |
| Accrued expenses                                                                                                                                                                                                  | 3,960,640 |   |   | 4,491,074 |   |
| Deferred revenue (amounts from related parties)                                                                                                                                                                   | 8,580,457 |   |   | 16,974,383 |   |
| Total current liabilities                                                                                                                                                                                         | 15,370,224 |   |   | 26,859,423 |   |
| Deferred revenue                                                                                                                                                                                                  | 119,531 |   |   | 154,187 |   |
| Redeemable warrants                                                                                                                                                                                               | — |   |   | 13,471,832 |   |
| Common stock warrant liability                                                                                                                                                                                    | 14,345,017 |   |   | 9,286,906 |   |
| TOTAL LIABILITIES                                                                                                                                                                                                 | 29,834,772 |   |   | 49,772,348 |   |
| COMMITMENTS AND CONTINGENCIES                                                                                                                                                                                     |   |   |   |   |   |
| Contingently redeemable series C preferred stock, 600 shares issued and outstanding (liquidation preference of $600,000)                                                                                          | 600,000 |   |   | 600,000 |   |
| SHAREHOLDERS' DEFICIENCY:                                                                                                                                                                                         |   |   |   |   |   |
| Preferred stock, $.01 par value;1,000,000 shares authorized                                                                                                                                                       |   |   |   |   |
| Series B convertible preferred stock, 130 shares issued and outstanding (liquidation preference of $13,000)                                                                                                       | 1 |   |   | 1 |   |
| Series E convertible preferred stock, 24,000 shares issued and outstanding (liquidation preference of $2,400,000) in 2011 and 59,000 shares issued and outstanding (liquidation preference of $5,900,000) in 2010 | 240 |   |   | 590 |   |
| Common stock $.01 par value; 150,000,000 authorized; 86,731,337 and 84,434,611 shares issued in 2011 and 2010, respectively                                                                                       | 867,313 |   |   | 844,345 |   |
| Capital in excess of par value                                                                                                                                                                                    | 276,315,144 |   |   | 260,600,989 |   |
| Less cost of 3,462,124 treasury shares in 2010                                                                                                                                                                    | — |   |   | (3,346,090 | ) |
| Accumulated deficit                                                                                                                                                                                               | (279,996,832 | ) |   | (278,809,945 | ) |
| Accumulated other comprehensive income                                                                                                                                                                            | 197,845 |   |   | 196,604 |   |
| Shareholders' deficiency                                                                                                                                                                                          | (2,616,289 | ) |   | (20,513,506 | ) |
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY                                                                                                                                                                    | $ | 27,818,483 |   |   | $ | 29,858,842 |   |

----

|                                                                   |
|-------------------------------------------------------------------|
|                                                                   |  |  |  |  |  |  |  |  |
|                                                              |   | Three Months Ended March 31, |
|                                                              |   | 2011 |   | 2010 |
| REVENUES                                                          |   |   |   |   |   |   |
| Net product revenues (including amounts from related parties:     |   |   |   |   |   |   |
| 2011 - $426,780; 2010 - $0)                                       |   | $ | 3,464,944 |   |   | $ | 7,103,756 |   |
| Royalties (including amounts from related parties:                |   |   |   |   |   |   |
| 2011 - $540,000; 2010 - $0)                                       |   | 600,813 |   |   | 52,356 |   |
| Other revenues (including amounts from related parties:           |   |   |   |   |   |   |
| 2011 - $8,393,926; 2010 - $0)                                     |   | 8,428,582 |   |   | 16,787 |   |
| Total net revenues                                                |   | 12,494,339 |   |   | 7,172,899 |   |
| COST OF PRODUCT REVENUES                                          |   |   |   |   |   |   |
| Cost of product revenues (including amounts from related parties: |   |   |   |   |   |   |
| 2011 - $388,133; 2010 - $0)                                       |   | 2,034,838 |   |   | 1,176,579 |   |
| Gross profit                                                      |   | 10,459,501 |   |   | 5,996,320 |   |
| OPERATING EXPENSES:                                               |   |   |   |   |   |   |
| Selling and distribution                                          |   | 57,842 |   |   | 3,250,319 |   |
| General and administrative                                        |   | 2,356,478 |   |   | 4,126,318 |   |
| Research and development                                          |   | 1,345,601 |   |   | 2,341,818 |   |
| Amortization of licensing right                                   |   | — |   |   | 1,261,182 |   |
| Total operating expenses                                          |   | 3,759,921 |   |   | 10,979,637 |   |
| Income (loss) from operations                                     |   | 6,699,580 |   |   | (4,983,317 | ) |
| OTHER INCOME (EXPENSE):                                           |   |   |   |   |   |
| Interest income                                                   |   | 1,525 |   |   | 1,620 |   |
| Interest expense                                                  |   | (3,888 | ) |   | (2,302,794 | ) |
| Change in fair value of derivative                                |   | — |   |   | (5,848,150 | ) |
| Change in fair value of redeemable warrants                       |   | (2,721,205 | ) |   | — |   |
| Change in fair value of stock warrants                            |   | (5,058,111 | ) |   | — |   |
| Other, net                                                        |   | (101,860 | ) |   | (110,685 | ) |
| Total other expenses                                              |   | (7,883,539 | ) |   | (8,260,009 | ) |
| Loss before taxes                                                 |   | (1,183,959 | ) |   | (13,243,326 | ) |
| State income taxes                                                |   | (2,928 | ) |   | (2,200 | ) |
| NET LOSS                                                          |   | $ | (1,186,887 | ) |   | $ | (13,245,526 | ) |
| NET LOSS PER COMMON SHARE:                                        |   |   |   |   |   |   |
| Basic and diluted                                                 |   | $ | (0.01 | ) |   | $ | (0.20 | ) |
|                                                              |   |   |   |   |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:             |   |   |   |   |   |   |
| Basic and diluted                                                 |   | 83,703,219 |   |   | 65,388,921 |   |

----

|                                    |
|------------------------------------|
|                                    |  |  |  |  |  |  |  |  |
|                               |   | Three Months Ended March 31, |
|                               |   | 2011 |   | 2010 |
| NET LOSS                           |   | $ | (1,186,887 | ) |   | $ | (13,245,526 | ) |
| Other comprehensive income (loss): |   |   |   |   |
| Foreign currency translation       |   | 1,241 |   |   | (8,818 | ) |
| COMPREHENSIVE LOSS                 |   | $ | (1,185,646 | ) |   | $ | (13,254,344 | ) |

----

| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)                  |
|-----------------------------------------------------------------------------|
|                                                                             |  |  |  |  |  |  |  |
|                                                                        | Three Months Ended March 31, |
|                                                                        | 2011 |   | 2010 |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                       |   |   |   |
| Net loss                                                                    | $ | (1,186,887 | ) |   | $ | (13,245,526 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities- |   |   |   |
| Depreciation and amortization                                               | 46,162 |   |   | 1,526,916 |   |
| Amortization on beneficial conversion features                              | — |   |   | 451,490 |   |
| Amortization on warrant valuation                                           | — |   |   | 331,857 |   |
| Change in value of derivative                                               | — |   |   | 5,848,150 |   |
| Change in value of redeemable warrants                                      | 2,721,205 |   |   | — |   |
| Change in value of stock warrants                                           | 5,058,111 |   |   | — |   |
| Recognition of deferred income                                              | (8,428,582 | ) |   | — |   |
| Provision for sales returns                                                 | 41,096 |   |   | 1,063,993 |   |
| Writedown of Striant inventories                                            | 58,612 |   |   | 14,001 |   |
| Share-based compensation                                                    | 200,280 |   |   | 561,651 |   |
| Non-cash interest expense on financing agreements                           | — |   |   | 546,995 |   |
| Loss on disposal of fixed assets                                            | 3,780 |   |   | — |   |
|                                                                        |   |   |   |
| Changes in assets and liabilities-                                          |   |   |   |
| (Increase) decrease in:                                                     |   |   |   |
| Accounts receivable                                                         | 1,124,084 |   |   | 965,183 |   |
| Inventories                                                                 | (375,793 | ) |   | (570,269 | ) |
| Prepaid expenses and other current assets                                   | (402,369 | ) |   | 88,202 |   |
| Other assets                                                                | 19,820 |   |   | (183 | ) |
| Increase (decrease) in:                                                     |   |   |   |
| Accounts payable                                                            | (2,564,839 | ) |   | (856,619 | ) |
| Other accrued expenses                                                      | (588,551 | ) |   | (133,833 | ) |
| Deferred revenue                                                            | — |   |   | (16,186 | ) |
| Net cash used in operating activities                                       | (4,273,871 | ) |   | (3,424,178 | ) |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                       |   |   |   |
| Purchase of property and equipment                                          | (4,705 | ) |   | (1,214 | ) |
| Net cash used in investing activities                                       | (4,705 | ) |   | (1,214 | ) |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                       |   |   |   |
| Proceeds from exercise of stock options                                     | 2,043,744 |   |   | — |   |
| Proceeds from exercise of warrants                                          | 653,299 |   |   | — |   |
| Payments for purchase of treasury stock                                     | — |   |   | (25,556 | ) |
| Dividends paid                                                              | (7,500 | ) |   | (7,500 | ) |
| Net cash provided by (used in) financing activities                         | 2,689,543 |   |   | (33,056 | ) |

----

|                                                                              |
|------------------------------------------------------------------------------|
|                                                                              |  |  |  |  |  |  |  |
|                                                                         | Three Months Ended March 31, |
|                                                                         | 2011 |   | 2010 |
|                                                                         |   |   |   |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH                                      | 18,265 |   |   | (14,924 | ) |
| NET DECREASE IN CASH                                                         | (1,570,768 | ) |   | (3,473,372 | ) |
| CASH, BEGINNING OF PERIOD                                                    | 21,630,979 |   |   | 14,757,615 |   |
| CASH END OF PERIOD                                                           | $ | 20,060,211 |   |   | $ | 11,284,243 |   |
|                                                                         |   |   |   |
| SUPPLEMENTAL INFORMATION                                                     |   |   |   |   |   |
| Interest paid                                                                | $ | — |   |   | $ | 800,000 |   |
| Taxes paid                                                                   | $ | 31,728 |   |   | $ | 8,500 |   |
| NON-CASH FINANCING ACTIVITIES                                                |   |   |   |
| Reclassification of redeemable warrant liability to capital in excess of par | $ | 16,193,037 |   |   | $ | — |   |

----

|     |                                  |
|-----|----------------------------------|
| (1) | SIGNIFICANT ACCOUNTING POLICIES: |

|     |                      |
|-----|----------------------|
| (2) | WATSON TRANSACTIONS: |

----

|     |                   |
|-----|-------------------|
| (3) | DEFERRED REVENUE: |

|        |
|--------|
|        |  |  |  |  |  |  |  |  |
|   |   | March 31 |   | December 31 |
|   |   | 2011 |   | 2010 |
|   | Net deferred revenue - Watson | 8,580,457 |   |   | 16,974,383 |   |
|   |   |   |   |   |
|   | Deferred revenue - other | 119,531 |   |   | 154,187 |   |
|   |   |   |   |   |
|   | Total deferred revenue | $ | 8,699,988 |   |   | $ | 17,128,570 |   |
|   |   |   |   |   |

|     |                                                 |
|-----|-------------------------------------------------|
| (4) | REVENUE RECOGNITION AND SALES RETURNS RESERVES: |

----

|                                 |
|---------------------------------|
|                                 |  |  |  |  |  |  |  |
|                            | Three Months Ended March 31, |
|                            | 2011 |   | 2010 |
| Balance at beginning of year    | $ | 2,663,648 |   |   | $ | 1,883,623 |   |
| Provision:                      |   |   |   |   |
| Related to current period sales | 41,096 |   |   | 319,078 |   |
| Related to prior period sales   | — |   |   | 744,915 |   |
|                            | 41,096 |   |   | 1,063,993 |   |
| Returns:                        |   |   |   |
| Related to current period sales | — |   |   | (7,879 | ) |
| Related to prior period sales   | (283,880 | ) |   | (332,770 | ) |
|                            | (283,880 | ) |   | (340,649 | ) |
| Balance at end of quarter       | $ | 2,420,864 |   |   | $ | 2,606,967 |   |

|     |              |
|-----|--------------|
| (5) | INVENTORIES: |

|                   |
|-------------------|
|                   |  |  |  |  |  |  |  |
|              | March 31, 2011 |   | December 31, 2010 |
| Finished goods    | $ | 1,859,593 |   |   | $ | 1,491,057 |   |
| Raw materials     | 1,043,795 |   |   | 1,095,150 |   |
| Total Inventories | $ | 2,903,388 |   |   | $ | 2,586,207 |   |

|     |                |
|-----|----------------|
| (6) | NOTES PAYABLE: |

----

|     |                               |
|-----|-------------------------------|
| (7) | FINANCING AGREEMENTS-STRIANT: |

|     |                         |
|-----|-------------------------|
| (8) | GEOGRAPHIC INFORMATION: |

----

|                                                     |
|-----------------------------------------------------|
|                                                     |  |  |  |  |  |  |  |
|                                                | NetRevenues |   | IdentifiableAssets |
| As of and for the three months ended March 31, 2011 |   |   |   |
| United States                                       | $ | 9,810,525 |   |   | $ | 23,131,187 |   |
| Switzerland                                         | 2,683,814 |   |   | 4,687,296 |   |
| Total                                               | $ | 12,494,339 |   |   | $ | 27,818,483 |   |
| As of and for the three months ended March 31, 2010 |   |   |   |
| United States                                       | $ | 4,649,037 |   |   | $ | 32,586,890 |   |
| Switzerland                                         | 2,363,620 |   |   | 5,674,320 |   |
| Other countries                                     | 160,242 |   |   | — |   |
| Total International                                 | 2,523,862 |   |   | 5,674,320 |   |
| Total                                               | $ | 7,172,899 |   |   | $ | 38,261,210 |   |

Table of Contents

|     |                                             |
|-----|---------------------------------------------|
| (9) | LOSS PER COMMON AND POTENTIAL COMMON SHARE: |

|                                 |
|---------------------------------|
|                                 |  |  |  |  |  |  |  |
|                            | Three Months Ended March 31, |
|                            | 2011 |   | 2010 |
| NET LOSS                        | $ | (1,186,887 | ) |   | $ | (13,245,526 | ) |
| Less: Preferred stock dividends | (7,500 | ) |   | (7,500 | ) |
| NET LOSS APPLICABLE TO          |   |   |   |
| COMMON STOCK                    | $ | (1,194,387 | ) |   | $ | (13,253,026 | ) |
|                            |   |   |   |
| NET LOSS PER COMMON SHARE:      |   |   |   |
| Basic and diluted               | $ | (0.01 | ) |   | $ | (0.20 | ) |
|                            |   |   |   |
| WEIGHTED AVERAGE NUMBER OF      |   |   |   |
| COMMON SHARES OUTSTANDING:      |   |   |   |
| Basic and diluted               | 83,703,219 |   |   | 65,388,921 |   |

|      |                   |
|------|-------------------|
| (10) | LEGAL PROCEEDINGS |

----

|      |                           |
|------|---------------------------|
| (11) | STOCK-BASED COMPENSATION: |

|                            |
|----------------------------|
|                            |  |  |  |  |  |  |  |
|                       | Three Months EndedMarch 31 |
| Stock Based Compensation   | 2011 |   | 2010 |
| Cost of revenues           | $ | 3,844 |   |   | $ | 23,234 |   |
| Selling and distribution   | — |   |   | 231,290 |   |
| General and administrative | 171,290 |   |   | 264,211 |   |
| Research and development   | 25,146 |   |   | 42,916 |   |
| Total                      | $ | 200,280 |   |   | $ | 561,651 |   |

|      |                                      |
|------|--------------------------------------|
| (12) | FAIR VALUE OF FINANCIAL INSTRUMENTS: |

|     |                            |
|-----|----------------------------|
| 13. | RELATED PARTY TRANSACTIONS |

----

|                                                  |
|--------------------------------------------------|
|                                                  |  |  |  |  |  |  |  |
|                                             | Three Months EndedMarch 31, |
|                                             | 2011 |   | 2010 |
| REVENUES                                         |   |   |   |   |   |
| Net product revenues                             | $ | 426,780 |   |   | $ | — |   |
| Royalties                                        | 540,000 |   |   | — |   |
| Other revenue (amortization of deferred revenue) | 8,393,926 |   |   | — |   |
| Total net revenues                               | $ | 9,360,706 |   |   | $ | — |   |
| COST OF PRODUCT REVENUES                         |   |   |   |   |   |
| Cost of product revenues                         | 388,133 |   |   | — |   |
| Gross profit                                     | $ | 8,972,573 |   |   | $ | — |   |
|                                             |   |   |   |
|                                             |   |   |   |
| Accounts Receivable                              | $ | 555,441 |   |   | — |   |

|      |                                   |
|------|-----------------------------------|
| (14) | RECENT ACCOUNTING PRONOUNCEMENTS: |

----

|      |                    |
|------|--------------------|
| (15) | SUBSEQUENT EVENTS: |

----

|                      |
|----------------------|
|                      |  |  |
|                 | Products: |
|                 |   |   |
| ProgesteroneProducts | - | CRINONE® 8% (progesterone gel) formerly marketed and sold by the Company, and now sold to Watson for resale in the U.S.;  |
|                 |   |
| -                    | CRINONE® 4% (progesterone gel) sold to Watson for resale in the U.S.; |
|                 |   |
| -                    | CRINONE® 8% sold to Merck Serono for resale outside the U.S.; |
|                 |   |
| -                    | PROCHIEVE® 8% (progesterone gel) formerly sold by the Company in the U.S.; and  |
|                 |   |
| -                    | PROCHIEVE® 4% sold to Ascend Therapeutics, Inc. for resale in the U.S pursuant to an agreement that terminated on July 23, 2010.  |
|                 |   |   |
| OtherProducts        | - | STRIANT® (testosterone buccal system) marketed and sold by the Company in the U.S. and    |
|                 |   |
|                 | STRIANT® sold to The Urology Company, Ltd. for resale in the U.K. |

----

----

----

|                      |
|----------------------|
|                      |  |  |  |  |  |  |  |
|                 | Three Months Ended March 31, |
|                 | 2011 |   | 2010 |
| Cash flows:          |   |   |   |
| Operating activities | $ | (4,273,871 | ) |   | $ | (3,424,178 | ) |
| Investing activities | (4,705 | ) |   | (1,214 | ) |
| Financing activities | 2,689,543 |   |   | (33,056 | ) |

----

----

|                         |
|-------------------------|
|                         |  |  |  |  |  |
|                    | Three Months Ended March 31, |
|                    | 2011 |   | 2010 |
| Risk free interest rate | 2.16 | % |   | — |   |
| Expected term           | 4.75 |   |   | — |   |
| Dividend yield          | — |   |   | — |   |
| Expected volatility     | 92.68 | % |   | — |   |

----

----

----

|     |          |
|-----|----------|
| (a) | Exhibits |

|      |
|------|
|      |  |
| 10.1 | Asset Purchase Agreement dated April 20, 2011, between Actient Pharmaceuticals LLC, and Columbia Laboratories, Inc. (1) |
| 10.2 | License Agreement dated April 20, 2011, between Actient Pharmaceuticals LLC, and Columbia Laboratories, Inc. (1) |
| 10.3 | U.S. Supply Agreement Assignment dated April 20, 2011, between Mipharm S.p.A., and Columbia Laboratories (Bermuda), Ltd. (1) |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of the Company.* |
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of the Company.* |
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** |
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** |

|     |
|-----|
|     |  |
| *   | Filed herewith. |
| **  | Furnished herewith. |
| (1) | Incorporated by reference to the Registrant’s Current Report on Form 8-K, dated April 20, 2011. |

----